Introduction
A drug will be granted a license to be sold in a specific jurisdiction once it receives approval from the relevant regulatory body that assesses its quality, efficacy, and safety. Regulatory bodies include the Therapeutic Goods Administration (TGA) for Australia, the European Medicines Agency (EMA) for Europe, and the Food and Drug Administration (FDA) for the United States. Such regulatory approval typically requires data from a phase III randomized controlled trial (RCT) that often comprises several hundred patients and spans many years. Such a trial is necessary to demonstrate the comparative efficacy and safety of the new drug. This is the key final step of a process from drug discovery to regulatory approval that typically requires 10 to 15 years, the cost of which has been estimated at more than US $1 billion per approved drug [1] .
There are issues, however, with requiring phase III trial data before granting approval for some conditions. For diseases with small patient populations, the potential market size may be insufficient to justify the substantial development costs. Indeed, for very rare diseases, there may not be even enough patients to conduct such a phase III trial. For severely life-threatening diseases with few or no effective treatment options, there may be drugs that already indicate transformational clinical benefit in early-stage single-arm phase I or II trials. Denying patients access to such therapies until phase III trials have been completed raises serious ethical issues. Thus, there is a demand and need for certain drugs to receive regulatory approval earlier in the developmental pathway, without delaying access until supportive comparative phase III data are available.
Both the EMA and FDA regulatory bodies have several wellestablished expedited registrational programs available for promising new treatments for severe diseases with high unmet need (typically cancers). These programs allow patients earlier access in their developmental pathway through expedited assessment as well as access on a less mature data package conditional on the sponsor conducting further studies to validate the degree of clinical benefit. Thus, the EMA will grant accelerated approval and conditional approval [2] , whereas the FDA has an accelerated-approval program as well as fast-track designation and priority reviews [3] . Indeed, previous research has demonstrated that the FDA has approved 28 oncologics across 37 indications [4] and the EMA 15 oncologics across 24 indications on the basis of data packages in which the pivotal trial was not a comparative phase III study (excluding pediatric indications or new formulations, which are well recognized as not requiring a full phase III data package for market access) [5] . Interestingly, in Europe, the clinical data packages that led to EMA approval for a number of these treatments contributed to the receipt of favorable pricing and reimbursement status by key European health technology assessment (HTA) bodies [6] .
Recent reforms by these regulatory bodies will enable yet more drugs to gain regulatory approval at potentially even earlier points in their developmental pathway. Since January 2013, FDA breakthrough status has given drugs for severe diseases expedited review where preliminary clinical evidence demonstrates substantial improvement over existing therapies [3] . Indeed, under this pathway two drugs have been approved on a data package supported by phase I data alone (ceritinib in non-small cell lung carcinoma [April 2014 ] and pembrolizumab in melanoma [September 2014] [7, 8] ). In April 2014, the EMA announced an adaptive reimbursement pilot program, a new paradigm in regulatory approval in which initial access to patients with very severe unmet need will be granted on very early-stage data; as more mature data become available, the patient population will be expanded [9] .
The Australian regulatory body, the TGA, has no such expedited registrational programs for treatments of severe conditions that lack effective alternatives. Furthermore, once regulatory approval has been granted, additional delays are often encountered when the drug seeks public reimbursement through the Australian HTA body: The Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC appraises drugs on the basis of their clinical and cost-effectiveness, and often requires drugs to be submitted multiple times to achieve reimbursement [10] . The entire process in Australia, from initial application to the TGA to gaining listing on the Pharmaceutical Benefits Scheme (PBS) and achieving complete public reimbursement, took an average of 31.0 months in 2013 [11] . This has resulted in delayed access for oncology medicines in Australia to a greater extent than in other developed markets [11] . This issue is particularly pertinent in Australia, given that it has the highest age-standardized incidence of cancer in the world [12] .
This research aimed to define the conditions under which drugs lacking phase III supportive trial data could achieve both TGA regulatory approval and public reimbursement through PBAC approval and PBS listing.
Methods
All publicly available TGA Australian Public Assessment Reports (AusPARs) [13] and PBAC Public Summary Documents [14] up to October 1, 2014, were screened to determine on what level of supportive clinical trial evidence each submission was based. A total of 472 AusPARs and 438 Public Summary Documents were screened. Any appraisal for an oncology drug for which the main clinical study was not a comparative phase III trial was extracted. Pediatric indications and new formulations, which are well recognized as being approved on a less than fully comprehensive phase III trial data package, were excluded from this analysis. For the six AusPARs (covering a total of seven indications) and six Public Summary Documents (covering a total of nine indications) that were appraised on such a data package, the TGA and PBAC date, decision, trial package, and key rationale were extracted. Furthermore, any publicly available corresponding EMA European Public Assessment Reports [15] and FDA decision summaries [16] for these TGA-approved indications were extracted. The appraisal outcomes, dates, and key rational were then compared to provide perspectives on how TGA-approved therapies on data packages lacking comparative phase III data have been appraised by other major regulatory bodies.
Results
Starting with regulatory decisions, AusPARs were available for six oncologic drugs across seven indications on the basis of a data package lacking comparative phase III data ( Table 1) . Four of seven of these indications received full TGA approval and one of seven had received restricted approval, whereas one of seven was 
refused by the TGA. One of seven was approved only on appeal after an interim study report of a comparative phase III trial was made available.
TGA appraisals of oncology agents lacking comparative phase III data frequently made reference to the EMA guidelines on the Evaluation of Anticancer Medicinal Products in Man (EMEA/EWP/ 205/95 Rev 3 Corr). These guidelines have been adopted by the TGA and generally require provision of phase III data (comparing the drug to an established comparator) to obtain marketing approval. The submissions often note, however, that the TGA has previously approved oncology applications on the basis of phase II data in situations in which the evidence for efficacy is convincing and either 1) the condition is rare or 2) the condition is a lifethreatening one for which no other therapy is available. Indeed, the TGA note that for several of these submissions the primary end point is the overall response rate, which is not endorsed as a primary end point in this TGA-adopted EMA guidance. If these single-arm trials demonstrated sufficient follow-up to include survival end points, which indicated benefit over historical controls, however, this was considered acceptable. In the rejection case of pralatrexate, time-to-progression data were presented in addition to the primary end point overall response rate; patient time-to-progression comparisons are endorsed by the TGAadopted EMA guidelines. Comparisons of time to progression, however, were not clearly prespecified, and did not universally favor pralatrexate, resulting in the rejection of this oncologic.
Publicly available EMA reports were available for six of the seven TGA-appraised indications with highly congruent outcomes (Table 1) . Both the EMA and the TGA refused pralatrexate, both similarly restricted brentuximab in Hodgkin lymphoma, and both granted approval to brentuximab in systemic anaplastic large cell lymphoma, crizotinib in non-small cell lung carcinoma, and vismodegib in basal cell carcinoma. The only difference between the EMA and the TGA in terms of outcomes was that ofatumumab received restricted EMA approval but full TGA approval. Nevertheless, the wording of the final indications approved by the EMA and the TGA were highly aligned. The major difference was in the time taken to reach a decision, with the EMA issuing its final recommendations at an earlier time point than did the TGA for all the six indications by an average of almost 1 year (range 2-15 months; median 11.5 months, mean 11.8 months). In turn, the FDA issued its recommendations consistently earlier than did both the EMA and the TGA. Compared with the TGA, the FDA supplied recommendations an average of approximately 2 years before the TGA (range 7-47 months; median 25 months; mean 23.2 months). Furthermore, the FDA approved all the seven indications without restrictions.
Moving onto reimbursement decisions, the PBAC has appraised six oncologics across 10 indications on the basis of noncomparative phase III data (Fig. 1) . Six of the 10 indications received approval without restrictions on this basis, 2 of the 10 indications received restricted approval, and 2 of the 10 indications were rejected by the PBAC. It is noteworthy that only a proportion of AusPARs were made publicly available; therefore, several drugs that were appraised by the PBAC on the basis of data packages lacking comparative phase III data did not have a corresponding AusPAR.
Six of the indications were appraised by the PBAC on the basis of noncomparative phase II data, with 4 of 10 supported by caseseries data ( Table 2 ). The magnitude of supportive data alone did not appear to be correlated with the probability of drugs being accepted; four of four indications were approved without restrictions on the basis of case-series data versus one of three approved with more than one supportive phase II trial. Nine of 10 indications (all except cetuximab, which was rejected) were recognized by the TGA as being orphan indications, with the 4 indications approved on case-series data also being recognized by the PBAC as extremely rare disease subsets.
The PBAC deemed that all the 10 indications had relevant active comparators and all submissions presented historical control data versus these comparators against which economic modeling was undertaken (Table 3) . Only 3 of the 10 indications presented an economic evaluation based on a quality-adjusted life-year metric (only 1 of 3 was approved by the PBAC). Two of 10 presented cost/life-year gained data, and 4 of 10 presented cost/ responder analyses (those with case-series submissions), with 1 of 10 evaluated on a cost-minimization basis. All the five indications with a PBAC-accepted incremental costeffectiveness ratio whose range fell below AU $75,000 were approved, and only one above this threshold was approved (dasatinib in acute lymphoblastic leukemia), the only indication in which the PBAC accepted that the "Rule of Rescue" applied. The Rule of Rescue enables more favorable cost-effectiveness evaluation of any medicine that fulfils all the criteria: no Fig. 1 -Timeline of oncology appraisals by the PBAC on the basis of a pivotal trial data package lacking comparative phase III data. ALL, acute lymphoblastic leukemia; ASM, aggressive systemic mastocytosis; CML, chronic myeloid leukemia; CRC, colorectal cancer; DMSP, dermatofibrosarcoma protuberans; GBM, glioblastoma; HES-CEL, hypereosinophilic syndromechronic eosinophilic leukemia; LYG, life-year gained; PBAC, Pharmaceutical Benefits Advisory Committee; MDS/MPD, myelodysplastic/myeloproliferative diseases; sALCL, systemic anaplastic large cell lymphoma.
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alternative treatment, severe and life-threatening condition, very small number of patients, and provides substantial benefits [17] . The uncertainty inherent in conducting economic modeling on such limited clinical data, however, was frequently highlighted by the PBAC, such that it is likely that discounts will have been necessary to offset this uncertainty. Risk-sharing schemes can also be potentially used to address this, as recommended by the PBAC in its appraisal of imatinib in acute lymphoblastic leukemia.
In addition to the two submissions rejected, and the two indications receiving restricted approval, five of the six indications that received full PBAC approval without restrictions were rejected in their initial submission (all except brentuximab), receiving approval only upon resubmission (Table 4 ). In seven of the nine submissions that were rejected or restricted, a lack of suitable clinical data was cited as a key explanation, with incremental cost-effectiveness ratios recognized as being unacceptably high and uncertain in four of these (Table 4) . That insufficient clinical data was a key reason for many drugs being rejected or restricted indicates that the PBAC in addition to needing to find the therapy to be cost-effective is more demanding of survival data, greater patient numbers, and trial comparability to grant approval on this basis compared with the TGA.
Conclusions
Oncologic submissions that lack supportive phase III comparative data can attain TGA regulatory approval in Australia if they meet the following requirements (as outlined in the EMA guidelines on the Evaluation of Anticancer Medicinal Products in Man [EMEA/ EWP/205/95] [18] , adopted by the TGA):
1. Evidence for efficacy is convincing and either the 2. Condition is rare or 3. The condition is a life-threatening one for which no other therapy is available. 
ALL, acute lymphoblastic leukemia; ASM, aggressive systemic mastocytosis; CML, chronic myeloid leukemia; CRC, colorectal cancer; DFSP, dermatofibrosarcoma protuberans; GBM, glioblastoma; HES-CEL, hypereosinophilic syndrome-chronic eosinophilic leukemia; ICER, incremental cost-effectiveness ratio; LYG, life-year gained; MDS/MPD, myelodysplastic/myeloproliferative diseases; NA, not available/applicable; PBAC, Pharmaceutical Benefits Advisory Committee; QALY, quality-adjusted life-year; sALCL, systemic anaplastic large cell lymphoma.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C ( 2 0 1 5 ) 1 4 3 -1 4 9
Such a clinical data package lacking supportive phase III data can further support PBAC approval and public reimbursement if it also meets both the following conditions:
1. Can demonstrate satisfactory cost-effectiveness using acceptable cost-benefit metrics and 2. Contains more rigorous and substantial clinical data indicating dramatic benefits over the relevant comparators than was necessary for regulatory approval
The primary limitation to this analysis and the conclusions is that it is based on a small sample size (7 TGA-appraised indications and 10 PBAC-appraised indications). Thus, there may be additional/alternative circumstances, outside that which we have observed, in which the TGA and/or the PBAC will approve oncologics on such a limited data package. Nevertheless, the evidence presented here illustrates that the TGA has provided regulatory approval to oncologics that lack supportive phase III data through "side-by-side" uncontrolled, indirect comparisons to historical controls and/or other trial data. To offset uncertainty in making clinical claims on such limited trial data, however, the numerical differences need to be substantial, including in survival metrics, because the overall response rate is not endorsed as a primary end point in the TGA-adopted EMA guidelines on anticancer medicines. Despite the TGA having adopted the EMA guidance on evaluating anticancer medicines, there is evidence that the TGA uses a more rigid and stricter interpretation of the need for a phase III trial than does the EMA and also the FDA. This is illustrated through crizotinib, which was approved by the FDA under the accelerated-approval program on the basis of a pivotal phase II data in August 2011 and was approved by the EMA in July 2012 on the basis of pivotal phase II data with topline supportive phase III data, conditional on full phase III data being presented when available. In contrast, the TGA, which was presented with substantially the same data package as the EMA, rejected crizotinib until the interim study report of a comparative phase III study was made available in August 2013 [19] . The TGA explained that under the EMA-adopted guidelines, if crizotinib did have a "dramatic" benefit, then prospective confirmation in randomized, reference-controlled studies would be not only unnecessary but also unacceptable. Crizotinib, however, was undergoing several phase III studies versus standard chemotherapies in this clinical setting at that time [19] .
Although the TGA continues to lack an expedited or early review program for regulatory approval of promising therapies that treat severe diseases with few treatment options, in Europe and America there have been recent new regulatory initiatives on top of those already in place to enable even earlier patient access to such therapies, namely, breakthrough therapy status by the FDA and adaptive licensing by the EMA [3, 9] . This is occurring in tandem with a group of potentially transformational immunooncology therapies coming to market, which has started with the anti-programmed death-1/ligand agents. These agents have demonstrated the potential to show long-term survival in a broad range of advanced metastatic cancers. One such agent, nivolumab, has shown 1-, 2-, and 3-year survival rates of 84%, 48%, and 41%, respectively, in an advanced metastatic melanoma in a phase I trial [20] . Another agent, pembrolizumab, has already been licensed by the FDA under the breakthrough therapy status on the basis of a phase I trial [8] . Furthermore, in addition to several anti-programmed death-1/ligand agents in the pipeline, there are multiple combination products in development that promise even more impressive survival benefits. For example, nivolumab in combination with ipilimumab has demonstrated 1-and 2-year survival rates of 94% and 88%, respectively, in an advanced pretreated melanoma population in a phase I trial [21] . Thus, the advent of a multitude of potentially transformational oncology pipeline therapies alongside the addition of new channels for early EMA and FDA regulatory approval will undoubtedly increase the number of oncology therapies that will receive The PBAC deemed that the most plausible ICER at the submitted price was too high and uncertain
The PBAC considered cost-effective at a reduced price that produced an ICER of $45,000-$75,000/QALY ✓ Revised price 1L, first line; 2L, second line; 3L, third line; ALL, acute lymphoblastic leukemia; ASM, aggressive systemic mastocytosis; CML, chronic myeloid leukemia; CRC, colorectal cancer; DFSP, dermatofibrosarcoma protuberans; GBM, glioblastoma; HES-CEL, hypereosinophilic syndrome-chronic eosinophilic leukemia; ICER, incremental cost-effectiveness ratio; PBAC, Pharmaceutical Benefits Advisory Committee; MDS/MPD, myelodysplastic/ myeloproliferative diseases; QALY, quality-adjusted life-year; RSA, risk-sharing agreement; sALCL, systemic anaplastic large cell lymphoma.
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regulatory approval on the basis of clinical data packages lacking comparative phase III data by these bodies. Thus, without an expedited regulatory approval process for market access, Australian patients run the risk of experiencing substantial delays in receiving innovative new therapies, compared with their European and American counterparts. Australia would be wise to explore expedited access programs similar to the ones in the United States and the European Union to enable more rapid patient access for promising pipeline agents that treat lifethreatening diseases that lack efficacious alternatives. Caution must be exercised over exactly how such an expedited regulatory program is set up, particularly in the context that failure rates in phase III trials are more than 50% in oncology [22] . Thus, approving drugs on an early-stage data package before the publication of phase III data could risk exposing patients to drugs that lack clinical benefits or cause harm. Indeed, only 21 of 55 oncology indications approved under the FDA acceleratedapproval pathway have presented confirmatory mature trial data and been converted to regular approval despite some being on the market for up to 9 years [23] . Furthermore, 10% (3 of 30) of the drugs that have conducted confirmatory trials have been subsequently withdrawn because of efficacy and/or safety concerns. This suggests that in the absence of confirmatory data submission being a strict, nonnegotiable requirement with a defined time limit, the FDA accelerated-approval pathway has and may continue to allow access to unsafe or inefficacious therapies.
Nevertheless, even if the TGA were to implement an expedited early access approval program, there are often substantial delays and sometimes insurmountable barriers to overcome between TGA approval and the PBAC issuing a positive recommendation, necessary for PBS listing and public reimbursement. Eighty percent of PBAC recommendations between 2005 and 2011 required multiple submissions before receiving approval [10] . Such delays in attaining reimbursement may be increasing, with the average time between TGA approval and PBS listing of cancer medicines growing from 14.6 months in 2003 to 31.0 months in 2013 [11] . For example, a particular key focus in Australia is melanoma, as the country with the greatest global agestandardized incidence rates [12] . Several recent key therapeutic advances in this disease have faced significant delays to public reimbursement in Australia. Ipilimumab was listed on the PBS only in August 2013 after three PBAC submissions [24] , despite being approved by the pan-Canadian Oncology Drug Review in May 2012 [25] , the National Institute for Health and Care Excellence (NICE) in December 2012 [26] , and the Scottish Medicines Consortium (SMC) in April 2013 [27] . Furthermore, vemurafenib has never been listed on the PBS, not receiving PBAC approval in two submissions [28] , despite being approved by the panCanadian Oncology Drug Review in June 2012 [29] , NICE in December 2012 [30] , and the SMC in December 2013 [31] . The increasing number of oncologics with companion biomarker diagnostic tests adds yet another source of delay to gaining reimbursement in Australia. This is because such tests must be approved by the Medical Services Advisory Committee (MSAC) and listed on the Medicare Benefits Scheme before PBS listing of the respective oncologic. MSAC appraisals are complex, and failure to meet its requirements can result in substantial delays to patient access. This is illustrated by crizotinib, a first-in-class oncologic targeting the 4% to 7% of the patients with non-small cell lung carcinoma with an ALKþ mutation. In addition to the delays in achieving TGA regulatory approval (detailed above), the PBAC deferred the crizotinib submission in November 2013 and again in March 2014 with the failure of the MSAC to recommend the ALK-mutation diagnostic test cited as key [32] . As of October 2014, crizotinib is yet to be approved by the PBAC or the MSAC, despite having already been approved by other key HTA bodies, including the Swedish Dental and Pharmaceutical Benefits Agency (TLV, February 2014) [33] , the pan-Canadian Oncology Drug Review (May 2013) [34] , and the SMC (October 2013).
Previous research has demonstrated that principally the same reduced data package used to gain EMA approval has been sufficient to gain favorable pricing and reimbursement by key European HTA bodies [6] . The Transparency Commission (France) fully reimbursed 14 of 14 (100%) such oncologics, with 10 of 14 obtaining Improvement of Medical Benefit (Amelioration du Service Medical Rendu -ASMR) assessments of I to III. Six of 6 (100%) oncologics appraised by the Federal Joint Commission (Gemeinsame Bundesausschuss -G-BA, Germany) were deemed to offer some added benefit, avoiding reference pricing, with NICE approving 5 of 8 (63%), the SMC 6 of 11 (55%), and the TLV 7 of 7 (100%). At first glance, the PBAC approving eight such indications seems favorable in comparison to major European obligatory cost-utility HTA bodies. Four PBAC-approved indications, however, comprised a single submission for four rare indications of imatinib, which no other European HTA body (except the Transparency Commission) appraised. Furthermore, all the drugs approved by the PBAC on a data package lacking comparative phase III data except one were approved in either 2007 or 2008. Indeed, since the end of 2008, only two drugs have been appraised by the PBAC on such a data package, only one of which was approved.
TGA-approved drugs that are not listed on the PBS are available to Australian patients only through the private sector. Given the extremely high cost of many of these agents (ipilimumab [Yervoy], cost 4AU $100,000 per patient before PBS subsidization), this is not a realistic avenue for widespread patient access. Drugs lacking TGA approval can be accessed by patients through the Special Access Scheme [35] . This is a TGAadministered program through which patients with severe diseases and no treatment alternatives can access drugs before regulatory approval. Approval is granted on a named-patient basis, and any prescription issued under this scheme is treated as a private prescription. Thus, such programs are at a substantial cost to the sponsor and/or the participating institutions. This provides temporary access until a drug is licensed and reimbursed; companies may withdraw such arrangements if the medicine does not achieve PBAC approval. Indeed, crizotinib, which is yet to receive PBS approval, had its Special Access Scheme terminated in June 2014. Interestingly, the UK medicines regulatory body, the Medicines and Healthcare Products Regulatory Agency, announced in April 2014 an Early Access to Medicines Scheme for unlicensed therapies that would be on a cohort patient basis and would be linked to a newly introduced coordinated NICE technology appraisal and National Health Service England commissioning process [36] , perhaps providing a model by which highly innovative therapies for severe diseases with few treatment options could gain access for Australian patients.
In summary, we have shown that despite lacking an expedited regulatory approval pathway for severe diseases that lack efficacious alternatives, the TGA can approve and the PBAC will reimburse drugs on the basis of data packages lacking comparative phase III data. The expansion of early access programs by the EMA and the FDA coupled with the lack of such an alternative for the TGA and continued delays to achieving PBAC reimbursement, however, may mean that Australian patients may continue to experience delays in access and that these will become further exaggerated over time. We recommend that Australia explore the ideas of Europe and the United States in expedited access programs and adaptive licensing to ensure that Australia patients with life-threatening diseases with no efficacious treatment options can receive timely access to promising therapies. To avoid the potential weaknesses of such an approach, mandatory comparative data collection should be considered alongside this. In addition, to speed up access to new drugs, it may be advisable ( 2 0 1 5 ) 1 4 3 -1 4 9 to investigate ways of reducing resubmissions to the PBAC and simplifying the process of approval for diagnostic tests.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C
Source of financial support: This research received no specific grant from any funding agency in the public, commercial, or not-forprofit sectors. Time and materials were available under PAREXEL International's routine research and development arrangements.
